Cariprazine in Three Special Different Areas: A Real-World Experience

Cariprazine is an antipsychotic medication which received approval from the US Food and Drug Administration for the treatment of schizophrenia in September 2015. Cariprazine is a dopamine D-3 and D-2 receptor partial agonist, with a preference for the D-3 receptor. Furthermore, although to a more limited extent, cariprazine also exhibits partial agonism at the level of 5-HT1A receptors, thus exerting an antidepressant effect in addition to the antipsychotic effect. The most commonly encountered adverse events are extrapyramidal symptoms and akathisia. Short-term weight gain appears infrequently. Cariprazine is not associated with any clinically meaningful alterations in metabolic variables, prolactin, or ECG QT interval. Cariprazine is also approved for the acute treatment of manic or mixed episodes associated with bipolar I disorder. Clinical trials of cariprazine are ongoing in patients with acute bipolar I depression and as adjunctive treatment to antidepressant therapy in patients with major depressive disorder. In this article, we present some significant clinical cases regarding the use of cariprazine, with the hope that our experience can provide insight or suggestions to be used in clinical practice.

Automated summary

Cariprazine is an antipsychotic medication approved for the treatment of schizophrenia, with a preference for dopamine D-3 receptors and also partial agonism at 5-HT1A receptors for an antidepressant effect. Common adverse events include extrapyramidal symptoms and akathisia. In addition to schizophrenia, cariprazine is also approved for the treatment of bipolar I disorder.